UK to save on generic medicines bill
Key points
- The British government expects to save about 300 million pounds ($545 million) a year on the cost of generic medicines to the state sector, under a five-year agreement signed with industry, officials said on Wednesday.
- The new deal allows for reductions in the price paid by the National Health Service for generic, or unpatented, medicines if the market rate offered by manufacturers to wholesalers falls.
- The previous scheme worked by setting a maximum price for generics.
- Jane Kennedy, the junior health minister, said the new arrangements would promote a more transparent and competitive market for generic drugs.
The British government expects to save about 300 million pounds ($545 million) a year on the cost of generic medicines to the state sector, under a five-year agreement signed with industry, officials said on Wednesday.
The new deal allows for reductions in the price paid by the National Health Service for generic, or unpatented, medicines if the market rate offered by manufacturers to wholesalers falls.
The previous scheme worked by setting a maximum price for generics.
Jane Kennedy, the junior health minister, said the new arrangements would promote a more transparent and competitive market for generic drugs.
Britain already has one of the highest rates of generic drug use in Europe, with unbranded prescription medicines accounting for more than half of the overall market by volume but less than 20 percent in terms of value.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Medicines & Treatments →Migraine Drug May Be Chapel Hill, N.C., Drug Maker's 'Billion Dollar Baby'
Trexima, an experimental migraine drug with blockbuster potential, is curing the headaches of Pozen's investors - at least for now. The Chapel Hill drug-development company struck out in two previous attempts to get a…
27 September 2005


